EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudieMultizentrische Studie

Real-World Effectiveness of Vedolizumab vs Anti-TNF in Biologic-naïve Crohn’s Disease Patients: A 2-year Propensity-score-adjusted Analysis from the VEDOIBD-Study

Bernd Bokemeyer iD, Sandra Plachta-Danielzik, Romina di Giuseppe, Philipp Efken, Wolfgang Mohl, Martin Hoffstadt, Thomas Krause, Axel Schweitzer, Elisabeth Schnoy, Raja Atreya, Niels Teich iD, Leo Trentmann und 3 weitere

Inflammatory Bowel Diseases · 02.05.2024 · 30 (5) · 746-756

DOI: 10.1093/ibd/izad138 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 31.07.2023. Verfasst von Bernd Bokemeyer und 14 weiteren Autor:innen. Beteiligte Einrichtung: Competence Network IBD, Kiel, Germany. Hauptthemen laut MEDLINE: Crohn Disease, Antibodies, Monoclonal, Humanized, Propensity Score, Gastrointestinal Agents. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Takeda GmbH Berlin, Germany.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The aim of this observational, real-world evidence, modified intention-to-treat (mITT) study based on prospectively collected data from the VEDOIBD registry was to compare the effectiveness of vedolizumab (VEDO) vs antitumor necrosis factor (anti-TNF) in biologic-naïve Crohn’s disease (CD) patients.

Methods

Between 2017 and 2020, 557 CD patients starting therapy with VEDO or anti-TNF were consecutively enrolled in 45 IBD centers across Germany. Per study protocol, the analysis excluded biologic-experienced patients and those with a missing Harvey-Bradshaw Index score, resulting in a final sample of 327 biologic-naïve CD patients. Clinical remission was measured using the Harvey-Bradshaw Index at the end of induction therapy and after 1 and 2 years. Switching to a different therapy was considered an outcome failure. Propensity score adjustment with inverse probability of treatment weighting was used to correct for confounding.

Results

The effectiveness of both VEDO (n = 86) and anti-TNF (n = 241) was remarkably high for induction treatment, but VEDO performed significantly less well than anti-TNF (clinical remission: 56.3% vs 73.9%, P < .05). In contrast, clinical remission after 2 years was significantly better for VEDO compared with anti-TNF (74.2% vs 44.7%; P < .05; odds ratio, 0.45; 95% CI, 0.22-0.94). Remarkably, only 17% of patients switched from VEDO to another biologic vs 44% who received anti-TNF.

Conclusions

The results of this prospective, 2-year, real-world evidence study suggest that the choice of VEDO led to higher remission rates after 2 years compared with anti-TNF. This could support the role of VEDO as a first-line biologic therapy in CD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseAntibodies, Monoclonal, HumanizedPropensity ScoreGastrointestinal AgentsHumansFemaleMaleAdultRemission InductionTumor Necrosis Factor-alphaProspective StudiesRegistriesGermanyTreatment OutcomeMiddle AgedInfliximabYoung AdultTumor Necrosis Factor Inhibitors

Stichwörter der Autor:innen

Crohn’s diseaseRWE comparisonanti-TNFreal-world evidencevedolizumab

Substanzen

vedolizumabAntibodies, Monoclonal, HumanizedGastrointestinal AgentsTumor Necrosis Factor-alphaInfliximabTumor Necrosis Factor Inhibitors

Autor:innen und Institutionen

  • Competence Network IBD, Kiel, Germany.
  • Interdisciplinary Crohn Colitis Centre, Minden, Germany.
  • Clinic of General Internal Medicine I, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Gastroenterology Practice, Minden, Germany.
  • Center for Gastroenterology Saar MVZ, Saarbruecken, Germany.
  • Gastroenterology Practice, Bremen, Germany.

ORCID-Profile: Bernd Bokemeyer, Niels Teich

Förderung

  • Takeda GmbH Berlin, Germany

Zitieren

APA

Bokemeyer, B., Plachta-Danielzik, S., di Giuseppe, R., Efken, P., Mohl, W., Hoffstadt, M., Krause, T., Schweitzer, A., Schnoy, E., Atreya, R., Teich, N., Trentmann, L., Ehehalt, R., Hartmann, P., & Schreiber, S. (2024). Real-World Effectiveness of Vedolizumab vs Anti-TNF in Biologic-naïve Crohn’s Disease Patients: A 2-year Propensity-score-adjusted Analysis from the VEDOIBD-Study. Inflammatory Bowel Diseases, 30(5), 746-756. https://doi.org/10.1093/ibd/izad138

Vancouver

Bokemeyer B, Plachta-Danielzik S, di Giuseppe R, Efken P, Mohl W, Hoffstadt M, et al. Real-World Effectiveness of Vedolizumab vs Anti-TNF in Biologic-naïve Crohn’s Disease Patients: A 2-year Propensity-score-adjusted Analysis from the VEDOIBD-Study. Inflammatory Bowel Diseases. 2024;30(5):746-756. doi:10.1093/ibd/izad138

BibTeX
@article{Bokemeyer2024,
  author = {Bokemeyer, Bernd and Plachta-Danielzik, Sandra and di Giuseppe, Romina and Efken, Philipp and Mohl, Wolfgang and Hoffstadt, Martin and Krause, Thomas and Schweitzer, Axel and Schnoy, Elisabeth and Atreya, Raja and Teich, Niels and Trentmann, Leo and Ehehalt, Robert and Hartmann, Petra and Schreiber, Stefan},
  title = {Real-World Effectiveness of Vedolizumab vs Anti-TNF in Biologic-naïve Crohn’s Disease Patients: A 2-year Propensity-score-adjusted Analysis from the VEDOIBD-Study},
  journal = {Inflammatory Bowel Diseases},
  year = {2024},
  volume = {30},
  number = {5},
  pages = {746--756},
  doi = {10.1093/ibd/izad138}
}
Kostenlos starten →